Company
BeOne Medicines (BeiGene)
3 active trials that select patients by a biomarker on marked.bio, across 1 biomarker.
Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.
Biomarkers
Drugs in these trials
Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).
Upcoming readouts
Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.
- 2026-11 Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors Phase 2 · MSI-H / dMMR
Trials
3 of 17 trials shown
-
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
Having locally advanced unresectable or metastatic solid tumors with MSI-H or dMMR
MSI-H / dMMRMSI-H/dMMR Solid Tumors
-
A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations
BG-85738tislelizumabcetuximab
Participants must have evidence of a RAS mutation defined as a nonsynonymous mutation in Kirsten rat sarcoma viral oncogene homolog (KRAS),…
KRAS G12DRAS Mutation, Advanced Solid Tumor, Metastatic Solid Tumor
-
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
BGB-58067BG-89894RAS(ON) Inhibitors
documented RAS mutation status or KRAS mutation is required for selected cohorts
KRAS G12CKRAS G12DAdvanced Solid Tumor
-
Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)
tislelizumabdocetaxel
…ous histology must provide evidence of not harboring sensitizing epidermal growth factor (EGFR) mutation tested by a histology-based method.
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer
-
Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer
…nt Treatment in Patients With Early-Stage (Stage II-III) Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer
MSI-H / dMMRColorectal Cancer
-
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
BGB-10188Zanubrutinibtislelizumab
…oma, urothelial carcinoma or participant with confirmed microsatellite instability-high \[MSI-H\] or mismatch repair deficient \[dMMR\] solid tumor, etc.).
MSI-H / dMMRChronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma
-
Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency
…fferentiation with HRD deficiency by CTC-HRD assay and/or deleterious germline or somatic mutation in BRCA1 or BRCA2
BRCA1/2 mutationMetastatic Castration-Resistant Prostate Cancer (mCRPC), Homologous Recombination Deficiency (HRD)
-
Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China
Confirmed deleterious or suspected deleterious germline BRCA1 or BRCA2 mutation
BRCA1/2 mutationHER2-negative Breast Cancer
-
Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors
…rian cancer (including fallopian cancer or primary peritoneal cancer), harboring germline BRCA1/2 mutation 4.
BRCA1/2 mutationAdvanced High-grade Ovarian Cancer, Triple Negative Breast Cancer
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
BG-60366
Histologically or cytologically confirmed diagnosis of NSCLC, carrying an EGFR activating mutation prior to receiving standard EGFR-tyrosine kinase inhibitor (EGFR-TKI)
EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer, Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
-
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
BGB-53038tislelizumabcetuximab
…r, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
KRAS G12CKRAS G12DMetastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Colorectal Cancer, Advanced Pancreatic Ductal Adenocarcinoma
-
A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
BGB-30813tislelizumab
…ell carcinoma, melanoma, Merkel cell carcinoma, mesothelioma, microsatellite instability (MSI)-high, tumor mutation burden (TMB)-high, or mismatch repair deficient solid tumors
MSI-H / dMMRAdvanced Solid Tumors
-
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
pamiparibtemozolomide
Participants with homologous recombination deficiency (HRD+) or known BRCA mutant ovarian cancer Previously received at least one line of platinum-containing therapy in th…
BRCA1/2 mutationLocally Advanced or Metastatic Solid Tumors
-
The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors
…rious or suspected deleterious germline or somatic breast cancer susceptibility gene 1/2 (BRCA1/2) mutations or with homologous recombination deficiency (HRD).
BRCA1/2 mutationMSI-H / dMMRSolid Tumors
-
Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors
i. non-small cell lung cancer (participants with documented epidermal growth factor receptor mutation or anaplastic lymphoma kinase rearrangement should have been excluded) ii. ovarian cancer…
EGFR exon 19 deletion / L858RALK fusionAdvanced Cancer
-
The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor
BGB-283
We simultaneously require patients with one of B-RAF, N-RAS, or K-RAS mutation positive solid tumor.
KRAS G12CKRAS G12DSolid Tumors
-
Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors
BGB-283
One of B-RAF, N-RAS, or K-RAS mutation positive solid tumor.
KRAS G12CKRAS G12DSolid Tumors
No trials match these filters.